Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01006395|
Recruitment Status : Recruiting
First Posted : November 2, 2009
Last Update Posted : July 13, 2016
Less than 20% of men in whom prostate cancer is diagnosed early die from it. Cardiovascular disease is the most common cause of death in men with early prostate cancer. A commonly used form of treatment for prostate cancer is androgen deprivation therapy (ADT). ADT, while effective for the treatment of prostate cancer, has been linked to undesirable side effects, such as an increased risk of bone fractures and diabetes. Bisphosphonates, a class of drugs that prevent bone resorption, have been show to reduce the loss of bone mineral density that occurs as a consequence of ADT, but the effects of bisphosphonates on preservation of bone architecture is unknown.
This project has two main goals:
To assess prospectively, in men with prostate cancer receiving ADT, the effect of:
- the intravenous bisphosphonate zoledronic acidon ADT-induced microarchitectural decay of bone structure.
- ADT on insulin resistance and glucose metabolism. We will recruit 100 ambulatory men with non-metastatic prostate cancer who are about to commence a three year course of ADT as per routine clinical practice at Austin Health. Men will be randomised to receive either intravenous zoledronic acid (Aclasta, Novartis Pharmaceuticals) or placebo at baseline and after 12 months of ADT. Men with contraindications to zoledronic acid will be excluded from the study. All 100 study subjects will have clinical and laboratory assessment at baseline, and at 3, 6, 12, 18 and 24 months (study end), and imaging studies at baseline and at 6, 12 and 24 months.
The study protocol is outlined in more detail below (Please see flow chart included in the in
Clinical and laboratory assessment:
Full medical history, physical examination and quality of life assessment using the SF-36 questionnaire. Laboratory studies will include: oral glucose tolerance test (3, 12 and 24 months Commercial-in-Confidence only) and measurements of measure total testosterone, fasting glucose, C-peptide, HBA1c, bone turnover markers.
- Bony micro-architecture by high resolution quantitative computed tomography
- Bone mineral density and body composition by DEXA This project will have no direct benefit for the subjects involved in this study; however, it will improve our understanding on the effect of zoledronic acid on bone microarchitecture in men with prostate cancer receiving ADT. It will also help us to better understand the effect of ADT on insulin resistance and glucose metabolism.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Zoledronic acid Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2018|
Active Comparator: zoledronic acid
Drug: Zoledronic acid
|Placebo Comparator: Placebo||
- Bone microarchitecture [ Time Frame: 24 months ]
- Insulin resistance [ Time Frame: 24 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006395
|Contact: Mathis Grossmann, MD, PhD, FRACPfirstname.lastname@example.org|
|Heidelberg, Victoria, Australia, 3084|
|Contact: Grossmann 61394965000|
|Principal Investigator: Mathis Grossmann, MD PhD FRACP|